Veloject Product Concept San Francisco, CA | Pain Management San Francisco, CA

Reinventing the Injection Sequence

23-27% of Orthopedic Surgeons have required time of from work due to injury or illness
8% of Orthopedic Surgeons required longer than 3 weeks off because of injury.
36% of injured surgeons reported pain from an occupational injury “at least “minimally impacted” their performance
43% of injured surgeons were forced to take a break from work.

Deliver pharmaceutical compounds to the targeted tissue locations.
Facilitate convenient and comfortable application of fluids in precisely prescribed dosages.
Improve visualization and access to deeper tissue with increasing confidence and less obscuration.
Reduce the fatigue and fine-muscle strain associated with manual manipulation of plunger devices.
Potentially enable a faster surgical procedure with less physical effort.

Skepticism among HCPs and hospital buyers persists around the clinical efficacy and reproducibility of Exparel®
Selected community observations suggest that ~60% of the time, Exparel® works approximately 36 hours.
Surgeons often rely on a larger 20-gauge needle due to time constraints and physical fatigue concerns.
Many physicians accept the clinical uncertainties because pain control is so important for their patients and their paying institutions.
But many more do not.

The average orthopedic physician age &
practice size are increasing.
Demographic factors mean the suitability & attractiveness
of the VeloJect technology will increase
& improve over time.
High volume physicians demand
user-centered solutions.
Surgeons are increasingly older, less patient, and fatigued by
cumbersome & non-optimized technologies.

Sources:

Cherf, John MD. A Snapshot of U.S. Orthopaedic Surgeons: Results from the 2018 OPUS Survey (via AAOS Now). September 1, 2019.
American Academy of Orthopaedic Surgeons. www.aaos.org.

Our focus categories represent 90% of the company’s estimated addressable market.
Many of these procedures are performed by the same specialist surgeon (therefore, cross-category, the VeloJect customer is the same).
Providing training to surgeons on the safe and effective use of VeloJect is more readily attainable with greater applicability to more procedures.
Physicians performing orthopedic procedures are already very familiar with the action and the potential benefit of intraop pain control.
The ongoing move to an outpatient setting for these elective procedures means patient satisfaction and efficient post-op management are high priorities.

VeloJect has identified multiple predicate devices and obtained expert regulatory opinion that FDA is likely to accept the product in its current embodiment via the 510(k) clearance process.
VeloJect is presently running all design & development activities through an enterprise level QMS (Quality Management System)
VeloJect employs experienced engineering experts (mechanical, electrical and software) in order to maintain an attractive timeline for the 1st generation device’s DHF completion.

VeloJect believes that involving high-profile, high-credibility physicians through its Clinical Advisory Board is important for all aspects of product development and commercialization.
Onboarding additional Clinical Advisory Board members will pave the way for a more technologically advanced and increasingly commercially accepted VeloJect product portfolio.

VeloJect is pursuing several highly attractive fundamental improvement opportunities in the design and feature set of the injection technology.
Following the initial 510(k) clearance, VeloJect intends to focus on these new innovations through our 2nd generation product development program
The next generation product holds great potential for exciting new applications and enhancements.

VeloJect has completed its initial funding round and achieved its major milestones relating to the working prototype, IP filings, written legal & regulatory opinions, and contract manufacturer selection
VeloJect is on the path to obtaining 510(k) clearance and entering the US marketplace.
VeloJect has the potential to revolutionize fluid injections, particularly in light of ongoing questions and challenges relating to efficacy of the injection sequence.